Drug intelligence / Profile preview

fluoxetine + DHEA

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

A combination of fluoxetine, a selective serotonin reuptake inhibitor (SSRI) antidepressant, and DHEA (dehydroepiandrosterone), a naturally occurring hormone that can be manufactured as a dietary supplement. This combination has shown synergistic effects in increasing progenitor cell proliferation in the adult hippocampus at lower doses of fluoxetine than would be effective alone, which may contribute to its antidepressant properties. The combination has also been studied for its effects on hypoglycemia responses in individuals with Type 1 diabetes and for treating canine aggression.

Targets

SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on fluoxetine + DHEA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluoxetine + DHEA.

Explore the full profile